Shenzhen De Wuchuang Shidai (沈德无创时代) develops a high‑end magnetic resonance‑guided phased‑array focused ultrasound system branded as the “magnetic wave knife” for precision non‑invasive treatment of tumors and neurological disorders. The company originates from Professor Chen Yazhu's team at Shanghai Jiao Tong University and combines multi‑disciplinary technologies (MR imaging guidance, phased‑array focusing, treatment planning, navigation and AI). It holds 100+ patents and software copyrights and has won multiple national and municipal research awards and program grants. Multiple products are in clinical registration or application pathways, and the company has partnerships with leading Chinese hospitals and research programs. Market assessments cited in the article estimate a potential addressable market of ~¥70 billion (700亿元) and note broad clinical applicability across >120 indications. The company is pursuing domestic commercialization and an international rollout while preparing for IPO guidance and broader industrial deployment. Shende Medical (Shanghai Shende Medical Instrument Technology Co.) develops an MRI‑guided, phased‑array high‑intensity focused ultrasound system branded as the “Magnetic Wave Knife” for noninvasive treatment of tumors and brain/neurological diseases. The system combines superconducting MR guidance, phased‑array focus, AI‑driven treatment planning and real‑time MR thermometry to enable multi‑focus, visible temperature‑feedback heat ablation. The company reports CE approval for its late‑stage metastatic bone tumor pain relief system; three products addressing uterine fibroids/adenomyosis, metastatic bone pain relief and breast tumors are in clinical trials, with domestic NMPA approval expected in 2022. It holds a developed IP portfolio (37 patent filings, 15 granted invention patents, patent valuation ~RMB 108M) and obtained a RMB 20M patent‑pledge credit line from Hangzhou Bank. Founded in May 2013 with a leadership team including founder Prof. Shen Guofeng and chief advisor Academician Chen Yazhu, the company is building production, commercialization and after‑sales capability and is preparing international expansion and capital market steps (Hong Kong and Sci‑Tech Board planning). Recent financing proceeds are earmarked for clinical trials, marketing and development of additional indications including Parkinson’s, essential tremor, glioma, prostate and thyroid tumors.

Total raised

$27M

Funding rounds

2

Latest round

Series D

Latest activity

Oct 2023